Which antidepressants are associated with the fewest stage N3 (slow‑wave sleep) arousals?

Which Antidepressants Cause the Least Stage N3 Arousals

Based on the most recent high-quality polysomnographic evidence, antipsychotics cause the fewest arousals overall, while among antidepressants specifically, those with strong 5-HT2A receptor antagonism (nefazodone, mirtazapine, trazodone) and agomelatine appear to preserve or enhance slow-wave sleep with minimal disruption, whereas SSRIs and SNRIs consistently fragment sleep architecture and should be avoided when N3 preservation is the priority. 1, 2

Understanding the Evidence Hierarchy

The 2026 polysomnographic study provides the most direct answer to your question: antipsychotics reduced arousals significantly (p = .004), while antidepressants as a class actually increased REM latency and periodic limb movements 1. This creates a clinical dilemma—if you need an antidepressant specifically, you must choose carefully.

Antidepressants Ranked by Sleep Architecture Impact

Best Options for Preserving N3 and Minimizing Arousals:

1. Mirtazapine

• Preserves restorative sleep stages through H1 antagonism and 5-HT2A/2C blockade 2
• Does not suppress REM sleep like SSRIs 2
• Guideline-recommended for insomnia with comorbid depression 3
• Caveat: Associated with weight gain 4

2. Trazodone (25-100 mg)

• Increases N3 significantly (SMD = 1.61, p = 0.0006) 5
• Decreases number of awakenings (SMD = -0.67, p < 0.00001) 5
• Reduces WASO (SMD = -0.42, p = 0.04) 5
• Guideline-recommended as first-line sedating antidepressant 6
• Caveat: 2017 AASM guidelines suggest NOT using trazodone for insomnia based on limited efficacy data 7, but 2022 meta-analysis contradicts this with robust polysomnographic improvements 5

3. Low-dose Doxepin (3-6 mg)

• AASM-recommended specifically for sleep maintenance 7
• Minimal anticholinergic effects at low doses 3
• Caveat: Higher doses have more anticholinergic burden 3

4. Agomelatine

• Preserves restorative sleep stages and improves circadian alignment through melatonergic properties 2
• Does not suppress REM sleep 2
• Caveat: Not available in all countries; requires liver function monitoring

5. Nefazodone

• Does NOT increase slow-wave activity above normal but preserves natural sleep architecture 8
• Does not suppress REM sleep unlike SSRIs 8
• Caveat: Hepatotoxicity risk; rarely prescribed 4

Worst Options (Avoid for N3 Preservation):

SSRIs (Paroxetine, Fluoxetine, Sertraline, Citalopram, Escitalopram)

• Consistently suppress REM sleep and fragment sleep continuity 2
• Increase REM latency markedly (p = .001) 1
• Increase periodic limb movements (p = .015) 1
• Paroxetine specifically increases insomnia risk (OR = 3.47 for reboxetine, but paroxetine also high) 9

SNRIs (Venlafaxine, Desvenlafaxine)

• Similar REM suppression and sleep fragmentation as SSRIs 2
• Venlafaxine has higher nausea/vomiting rates 4

Bupropion

• While it has fewer sexual side effects 4, it increases insomnia risk 9
• Not sedating; inappropriate for sleep preservation

Clinical Algorithm for Selection

Step 1: Assess Comorbidities

• If comorbid depression requiring full antidepressant dosing → Mirtazapine 15-45 mg
• If insomnia predominates with mild depression → Trazodone 50-100 mg or low-dose doxepin 3-6 mg
• If circadian misalignment present → Agomelatine (if available)

Step 2: Evaluate Contraindications

• Avoid trazodone if priapism risk concerns
• Avoid mirtazapine if weight gain unacceptable
• Avoid doxepin at higher doses if anticholinergic effects problematic
• Avoid nefazodone given hepatotoxicity

Step 3: Monitor Response

• If daytime drowsiness occurs with trazodone (OR = 2.53, p = 0.02) 5, reduce dose or switch to doxepin
• If appetite decreases with trazodone (OR = 2.81, p = 0.02) 5, consider mirtazapine instead

Step 4: Avoid Polypharmacy

• The 2026 study demonstrates dose-response relationship: greater psychotropic burden independently reduces arousal index but also prolongs REM latency 1
• Cumulative medication burden compounds sleep architecture disruption 1

Critical Pitfalls to Avoid

1. Do not use SSRIs/SNRIs if N3 preservation is the primary goal—they consistently fragment sleep despite treating depression 1, 2

2. Do not assume all "sedating" antidepressants are equivalent—trazodone increases N3, while SSRIs do not 5

3. Do not ignore the 2017 AASM guideline's negative recommendation on trazodone 7, but recognize the 2022 meta-analysis provides contradictory polysomnographic evidence of benefit 5—clinical judgment favors using trazodone given objective sleep improvements

4. Do not prescribe antidepressant doses too low to treat depression if depression is the primary diagnosis—low-dose sedating antidepressants are inadequate for major depression 3

5. Consider that antipsychotics (quetiapine 2.5-5 mg, olanzapine 2.5-5 mg) actually reduce arousals more effectively 1 but carry metabolic risks—reserve for refractory cases 6